Craig Overpeck - Doximity Senior Operations
| DOCS Stock | USD 58.27 0.44 0.76% |
Executive
Craig Overpeck is Senior Operations of Doximity
| Address | 500 3rd Street, San Francisco, CA, United States, 94107 |
| Phone | 650 549 4330 |
| Web | https://www.doximity.com |
Doximity Management Efficiency
The company has return on total asset (ROA) of 0.1183 % which means that it generated a profit of $0.1183 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.19 %, meaning that it created $0.19 on every $100 dollars invested by stockholders. Doximity's management efficiency ratios could be used to measure how well Doximity manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Heidi JD | GeneDx Holdings Corp | 57 | |
| SPHR GPHR | Humacyte | N/A | |
| Harold Alterson | Humacyte | N/A | |
| Eric Olivares | GeneDx Holdings Corp | N/A | |
| Britt Johnson | GeneDx Holdings Corp | N/A | |
| Tricia Truehart | GeneDx Holdings Corp | N/A | |
| Sabrina Osborne | Humacyte | N/A | |
| Sabrina Dunbar | GeneDx Holdings Corp | N/A | |
| Melanie Duquette | GeneDx Holdings Corp | N/A | |
| Jennifer Brendel | GeneDx Holdings Corp | N/A | |
| Kevin CPA | GeneDx Holdings Corp | 43 | |
| Karen Ponchner | GeneDx Holdings Corp | N/A | |
| Jami Biliboaca | GeneDx Holdings Corp | N/A | |
| Jerry Conway | GeneDx Holdings Corp | N/A | |
| Feras Hantash | GeneDx Holdings Corp | N/A | |
| Yang MD | Humacyte | 58 | |
| Shamik MD | Humacyte | 51 | |
| Jason Ryan | GeneDx Holdings Corp | 50 | |
| William Scheessele | Humacyte | 52 | |
| FACMG MD | GeneDx Holdings Corp | N/A | |
| Kevin Feeley | GeneDx Holdings Corp | 43 | |
Management Performance
| Return On Equity | 0.19 | ||||
| Return On Asset | 0.12 |
Doximity Leadership Team
Elected by the shareholders, the Doximity's board of directors comprises two types of representatives: Doximity inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Doximity. The board's role is to monitor Doximity's management team and ensure that shareholders' interests are well served. Doximity's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Doximity's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Perry Gold, Head Relations | ||
| Paul Jorgensen, Chief Officer | ||
| Jim Rivas, Head Communications | ||
| Anna Bryson, Chief Financial Officer | ||
| Joel Davis, Senior Product | ||
| Jennifer JD, General Secretary | ||
| Bruno Miranda, Senior Engineering | ||
| Nate Gross, Co-Founder, Chief Strategy Officer | ||
| Jey Balachandran, Chief Technology Officer | ||
| Craig Overpeck, Senior Operations | ||
| Jeffrey Tangney, Chief Executive Officer, Co-Founder | ||
| Nate MD, CoFounder Officer | ||
| Jennifer Chaloemtiarana, General Secretary | ||
| Shari Buck, Co-Founder, Senior Vice President of People and Operations |
Doximity Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Doximity a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.19 | ||||
| Return On Asset | 0.12 | ||||
| Profit Margin | 0.34 % | ||||
| Operating Margin | 0.41 % | ||||
| Current Valuation | 10 B | ||||
| Shares Outstanding | 128.14 M | ||||
| Shares Owned By Insiders | 2.71 % | ||||
| Shares Owned By Institutions | 93.05 % | ||||
| Number Of Shares Shorted | 7.43 M | ||||
| Price To Earning | 67.68 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Doximity Stock Analysis
When running Doximity's price analysis, check to measure Doximity's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Doximity is operating at the current time. Most of Doximity's value examination focuses on studying past and present price action to predict the probability of Doximity's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Doximity's price. Additionally, you may evaluate how the addition of Doximity to your portfolios can decrease your overall portfolio volatility.